12:00 AM
 | 
Jun 02, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PLX3397: Additional Phase I data

Data from 14 evaluable patients with advanced pigmented villonodular synovitis (PVNS) in an extension cohort of an open-label, U.S. Phase I trial in about 150 patients with advanced solid tumors showed that once-daily 1,000 mg oral PLX3397 led to 11 partial responses and 3 cases of stable disease. Mean tumor size reduction was 61% and clinical improvements were observed in pain,...

Read the full 283 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >